1 ADNI2 - Private Partner Scientific Board (PPSB) Susan De Santi (Piramal Pharma, Inc.), PPSB Chair.

Slides:

Advertisements

Similar presentations

NEWMEDS – the work leading to these results has received funding from the Innovative Medicines Initiative Joint Undertaking (IMI) NEWMEDS Novel MEthods.

Advertisements

Forsyth.schoolwires.com Ways People Use Grades Communication to parents and others Student self-evaluation Select, identify, or group students Provide.

Connecting with Industry Heather M Wallace Industrial Liaison Group Medical Sciences and Medicine.

E5 Experiences in Japan Examples with unfavorable outcome How can we improve? Masuhiro Kato, PhD Chair, EFPIA Japan Technical Subcommittee (AstraZeneca.

December, NEED FOR VALIDATED BIOMARKERS FOR AD TRIALS Biomarkers useful in Phase 2 to make decisions about Phase 3 (e.g. doses) Biomarkers useful.

The Open Innovation Center Susie Stephens, Principal Research Scientist, Eli Lilly.

Facilities Management 2013 Manager Enrichment Program U.Va.’s Strategic Planning Initiatives Colette Sheehy Vice President for Management and Budget December.

U.S. Department of the Interior U.S. Geological Survey USGS Digital Aerial Mapping Camera Status CRSS/ASPRS Specialty Conference October 2007 USGS Remote.

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April

ADNI 3 Clinical Core Plans

Discovery of new medicines through new models of collaboration Simon Ward Professor of Medicinal Chemistry & Director of Translational Drug Discovery Group.

Research & Innovation International Rare Disease Consortium: Data Sharing Policy 3 rd International Traumatic Brain Injury Research Meeting Catherine BERENS.

Howard Fillit, MD Executive Director Improving Animal Trials for Alzheimer’s Disease: Recommendations for Best Practices.

Jacquie Westwood UK Genetic Testing Network.  Approving UKGTN member labs who provide quality assured tests  Acknowledgment – UKGTN Laboratory Membership.

Genetics Core Update & Planning ADNI-2 Steering Committee Philadelphia April 28, 2014 Andy Saykin Indiana University

2014 “Towards an HIV Cure” symposium Melbourne The Role of a Public-Private Partnership in HIV Cure Mike McCune, MD, PhD University of California, San.

ADNI Private Partner Scientific Board (PPSB) Update Susan De Santi, PhD 2015 Chairperson WW ADNI Meeting July 17, 2015.

1 The ACTION Public-Private Partnership: Background, Rationale, and Objectives Bob A. Rappaport, M.D. Director Division of Anesthesia, Analgesia, and Addiction.

A PPP managed by FNIH Partners are NIH, FDA, CMS, and private industry Barbara B. Mittleman, M.D. Director, NIH PPP Program Bioinformatics Forum March.

1 Collaborative Provision and External Examining Nicola Clarke Centre for Academic Standards and Quality Enhancement (CASQE)

©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar.

The Quantitative Imaging Network (QIN) Robert Nordstrom, Ph.D. Larry Clarke, Ph.D.

12/07/20101 Bidder’s Conference Call: ARRA Early On ® Electronic Enhancement to Individualized Family Service Plans (EE-IFSP) Grant and Climb to the Top.

The Practical Art of Endpoint Selection: Industry Perspectives A View from the Pharma Industry of the FDA Guidance on PROs Glenn A. Phillips, Ph.D. Director.

VICTR Funding Overview Vanderbilt Institute for Clinical and Translational Research (VICTR) June 22, 2012.

ESTELA Summer Workshop, 26 June 2013 The EU-SOLARIS project.

Development of Harvard Catalyst Imaging Consultation Service Simon K. Warfield, Ph.D. Valerie Humblet, Ph.D. on behalf of the CTSC Imaging Committee

Optimizing Data Standards Working Group Meeting Summary

©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar WW ADNI Washington, DC July 17, 2015.

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE Michael W. Weiner.

©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar ADNI Steering Committee Meeting Washington, DC April.

Setting the scene 9 September 2010 Setting the scene Alan Willson 9 September 2010.

The Clinical Trials Network for European Manufacturers Sally Schwarz, MS, RPh, BCNP Chair, Manufacturer’s Registry Sub-Committee SNM Clinical Trials Network.

WP3 Harmonization & Integration J. Lauterjung & WP 3 Group.

An Introduction to Becoming a Commissioning Organisation 30 April 2012 APACE Commissioning Event Simon Marshall Offender Services Co-Commissioning Group.

Effects of traumatic brain injury (TBI) & post traumatic stress disorder (PTSD) on Alzheimer’s disease (AD) in Veterans using ADNI (DOD ADNI) Michael.

NEUROGEN CORPORATION Alliance Management: View from the Smaller Side of the Alliance Thomas A. Pitler, Ph.D. VP Business Development.

The Role of the Internal and External Evaluators in Student Assessment Arthur Brown Advisor to the Quality Assurance and Accreditation Project Republic.

Biomarkers of Alzheimer’s Disease. Objectively mark Presence of neurodegenerative pathology Change in pathologic activity Purpose.

Laboratory of Neuro Imaging: Graduate Students Sarah K. Madsen Mentor: Paul M. Thompson, Ph.D. Committee: Susan Y. Bookheimer, Ph.D., Jamie D. Feusner,

Clinical and Translational Science Awards (CTSAs) Future Directions and Opportunities for ACNP investigators.

Alzheimer’s Association Efforts February 2014 Maria C. Carrillo, Ph.D. Vice President Medical & Scientific Relations Alzheimer’s Association American Society.

Quality Metrics of Performance of Research Ethics Committees Cristina E. Torres, PhD FERCAP Coordinator.

Defining HI Interoperability Vision December 10, 2013 Acting Director VA/DoD Health Information Sharing Office of Informatics and Analytics Veterans Health.

Who Are We? A Forum of Stakeholders Who Come together to Develop Science-based Solutions.

ADNI PPSB Update WW ADNI Meeting 22 July, An Eventful Year… Successful renewal of ADNI (ADNI-3) PPSB had an opportunity to contribute – PPSB/Biomarker.

ADNI Private Partner Scientific Board (PPSB) Update Veronika Logovinsky, MD, PhD 2017 Chairperson WW ADNI Meeting July 14, 2017.

Update of China-ADNI Kuncheng Li, MD. PhD.

ADNI3 Clinical core Paul Aisen Ron Petersen Mike Donohue

Diane Stephenson, PhD; Executive Director, CAMD

New Approaches to Metabolomics Research

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

Translational Research Why should you care about translational research? The public cares. Translation into therapies justifies spending on science.

Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar

Social Media Policy: DE Recommendations

Worldwide-ADNI Update Meeting Fairmont Royal York Hotel

Project Process Leading for Impact®: Building Future Leaders

ADNI Private Partner Scientific Board (PPSB) Update James Hendrix, PhD 2018 Chairperson WW ADNI Meeting July 20, 2018.

Repositories Lunch Meeting, Day 1

ADNI3 Clinical core Paul Aisen Ron Petersen Mike Donohue

ADNI Biomarker Core update

ADNI Private Partner Scientific Board (PPSB) Update Veronika Logovinsky, MD, PhD 2017 Chairperson WW ADNI Meeting July 14, 2017.

ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue

Ron Petersen & Paul Aisen

Update of China-ADNI Kuncheng Li, MD. PhD.

Carolina Mendoza-Puccini, MD

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups.

The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability.

Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative

Update Structure and Governance of the Seed Sector

Presentation transcript:

1 ADNI2 - Private Partner Scientific Board (PPSB) Susan De Santi (Piramal Pharma, Inc.), PPSB Chair

Current ADNI 2 PPSB Partners

Dorothy Jones-Davis Scientific Project Manager, Neuroscience Foundation for the NIH (301) FNIH Coordination and Organization

ADNI Cores MRI Cliff Jack PET Bill Jagust Biochemical Biomarker Les Shaw and John Trojanowski Biostatistics Laurel Beckett Clinical Ron Petersen & Paul Aisen Genetics Andy Saykin Neuropathology John Morris Publications Robert Green Pat Cole Adam Schwarz Holly Soares Johannes Streffer TBD Veronika Logovinsky Nandini Raghavan Nadeem Sarwar Leanne Munsie Enchi Liu Robert Paul Mark Schmidt Greg Klein Lee Honigberg RARC Tom Montine Enchi Liu Holly Soares PPSB Core Liaisons ADNI PI Mike Weiner PPSBPPSB PPSB working groups Biofluid Biomarkers WG Johan Luthman Clinical Endpoints WG Veronika Logovinsky, Nandini Raghavan 1.pAD/MCI Endpoints and Methods 2.Novel Tests for pre-MCI 3.List of Datasets 4.Computerized Cognitive Batteries PET Endpoints WG Mark Schmidt PPSB Chair Susan De Santi 2015 Informatics Art Toga

A goal of ADNI is to develop and validate methods for clinical trials PPSB has formalized a DD process for the selection of measures to be included in ADNI 3 and provide recommendations to ADNI Core leaders (e.g. clinical, cognitive, imaging, biomarkers, biofluids, etc.) An increase in commercial and competitive measures and markers being considered for ADNI; adding and subtracting precompetitive measures Inclusion of measures into ADNI 3 will be based on a solid analysis using objective criteria outline key criteria for consideration of measures assure transparency on how measures are identified, vetted and selected define clear, efficient timeline (e.g. < 4 months) avoid duplication of efforts achieve alignment for the final recommendation DD team assembled (no links to possible providers) for full vetted process Academics and industry scientists are working together Due Diligence (DD) Process for ADNI 3

Questions?